TickerFacts.

ImageneBio, Inc. (IMA): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2024-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$28.52M
Year ended 2025-12-31
$64.32M2020-12-31: $44.85M2021-12-31: $47.11M2022-12-31: $64.32M2023-12-31: $59.65M2024-12-31: $32.11M2025-12-31: $28.52M$28.52M
2020-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$28.52M-11.2%2026-03-10, From 2025-01-01
2024-12-31$32.11Mn/c2026-03-10, From 2024-01-01
2023-12-31$59.65M-7.3%2025-03-06, From 2023-01-01
2022-12-31$64.32M+36.5%2024-03-12, From 2022-01-01
2021-12-31$47.11M+5.0%2023-03-14, From 2021-01-01
2020-12-31$44.85Mn/a2022-03-17, From 2020-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
ImageneBio, Inc. (IMA)2025-12-31$28.52M-11.2%
Prokidney Corp. (PROK)2025-12-31$114.12M-10.6%
Pluri Inc. (PLUR)2026-06-30$15.09M+17.4%
Cardiff Oncology, Inc. (CRDF)2025-12-31$35.33M-4.1%
Inhibrx Biosciences, Inc. (INBX)2025-12-31$113.03M-44.5%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$2.37M-57.2%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$27.18M-34.9%
Humacyte, Inc. (HUMA)2025-12-31$69.30M-21.8%
Aligos Therapeutics, Inc. (ALGS)2025-12-31$69.45M-1.2%

Compare IMA, PROK, PLUR, CRDF side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗